Long-term Moon Shot | Editas Medicine
Updated
Editas Medicine is a clinical stage genome editing company,
With the help of CRISPR technology, it focuses on treating a range of serious diseases like:
-Leber Congenital Amaurosis type 10 (Genetic form of vision loss that leads to blindness in childhood) - EDIT-101 has recently entered phase 1/2 trial for the treatment, the very first time an in vivo CRISPR treatment enters clinical trials which with positive results could instantly make Editas a leader in this new field!
-Usher Syndrome 2A (Form of retinitis pigmentosa that also includes hearing loss)
-Treats sickle cell diseases and beta-thalassemia (A blood disorder that reduces the production of hemoglobin)
It is also
-In collaboration with Juno Therapeutics to develop engineered T cells for cancer!
-Agreement with Allergan Pharmaceuticals International Limited to innovate, discover and develop new gene editing medicines for a range of ocular disorder
-Collaboration with Asklepios BioPharmaceutical to develop therapy to treat neurological diseases
The company has a lot of potential ahead in upcoming years!
Let's get more technical!
UNDERVALUED, I believe now would be a good time to lock in a long term position due to those facts
-Recently had a public offering of 3.5M at $66 per share (Jan 21st)
-Pe Ratio -39x
-Fair Value of $479.88 US
-Fib Retracement to current lows indicates a potential entry for the long term
-LONG TERM TIMEFRAME 1D LOOKS PROMISING AS WELL!
With the help of CRISPR technology, it focuses on treating a range of serious diseases like:
-Leber Congenital Amaurosis type 10 (Genetic form of vision loss that leads to blindness in childhood) - EDIT-101 has recently entered phase 1/2 trial for the treatment, the very first time an in vivo CRISPR treatment enters clinical trials which with positive results could instantly make Editas a leader in this new field!
-Usher Syndrome 2A (Form of retinitis pigmentosa that also includes hearing loss)
-Treats sickle cell diseases and beta-thalassemia (A blood disorder that reduces the production of hemoglobin)
It is also
-In collaboration with Juno Therapeutics to develop engineered T cells for cancer!
-Agreement with Allergan Pharmaceuticals International Limited to innovate, discover and develop new gene editing medicines for a range of ocular disorder
-Collaboration with Asklepios BioPharmaceutical to develop therapy to treat neurological diseases
The company has a lot of potential ahead in upcoming years!
Let's get more technical!
UNDERVALUED, I believe now would be a good time to lock in a long term position due to those facts
-Recently had a public offering of 3.5M at $66 per share (Jan 21st)
-Pe Ratio -39x
-Fair Value of $479.88 US
-Fib Retracement to current lows indicates a potential entry for the long term
-LONG TERM TIMEFRAME 1D LOOKS PROMISING AS WELL!
Note
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.